Revolution Medicines, Inc. (RVMD)
209.23
-0.64
(-0.30%)
USD |
NASDAQ |
Sep 02, 16:00
211.34
+2.11
(+1.01%)
After-Hours: 20:00
Revolution Medicines Cash from Investing (Quarterly) : -1.659B for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.659B |
| March 31, 2026 | 172.62M |
| December 31, 2025 | 74.88M |
| September 30, 2025 | 24.85M |
| June 30, 2025 | 34.28M |
| March 31, 2025 | -15.95M |
| December 31, 2024 | -392.90M |
| September 30, 2024 | -21.47M |
| June 30, 2024 | 107.94M |
| March 31, 2024 | -247.97M |
| December 31, 2023 | -380.40M |
| September 30, 2023 | 77.35M |
| June 30, 2023 | -43.54M |
| March 31, 2023 | 3.996M |
| December 31, 2022 | -7.104M |
| Date | Value |
|---|---|
| September 30, 2022 | -123.44M |
| June 30, 2022 | 62.40M |
| March 31, 2022 | 44.02M |
| December 31, 2021 | 8.533M |
| September 30, 2021 | -30.18M |
| June 30, 2021 | -122.78M |
| March 31, 2021 | 2.309M |
| December 31, 2020 | 62.95M |
| September 30, 2020 | -100.97M |
| June 30, 2020 | -136.50M |
| March 31, 2020 | -59.72M |
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | -55.95M |
| March 31, 2019 | 5.761M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Tango Therapeutics, Inc. | -445.97M |
| Erasca, Inc. | 19.49M |
| Moderna, Inc. | 329.00M |
| Arrowhead Pharmaceuticals, Inc. | 43.68M |
| Intellia Therapeutics, Inc. | -141.57M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -387.32M |
| Cash from Financing (Quarterly) | 2.420B |
| Free Cash Flow | -1.232B |
| Free Cash Flow Per Share (Quarterly) | -1.847 |
| Free Cash Flow to Equity (Quarterly) | -1.143B |
| Free Cash Flow to Firm (Quarterly) | -365.82M |
| Free Cash Flow Yield | -2.96% |